QURE 250516 12.00P(QURE250516P12000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

QURE250516P12000

Watchlist

0.20
-0.19-48.72%

15min DelayClose Apr 30 16:00 ET

0.20High0.20Low

Intraday

5D
Daily

News

Leerink Partners Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $48
Moomoo NewsApr 30 03:32 ET · Ratings
Express News | Uniqure NV : Leerink Partners Raises Target Price to $48 From $44
ReutersApr 29 08:14 ET
Gene Therapy Developers Rise on Comments From FDA's Makary
Seeking AlphaApr 21 13:50 ET
Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $70 Price Target
BenzingaApr 21 13:41 ET
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
BenzingaApr 21 10:36 ET
Sector Update: Health Care Stocks Decline Late Afternoon
MT NewswiresApr 17 15:58 ET

Comments

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

$uniQure NV (QURE.US)$
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

1

$Channel Therapeutics (CHRO.US)$ $uniQure NV (QURE.US)$ $Baijiayun (RTC.US)$

4/17/25

3

$uniQure NV (QURE.US)$
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

Now I’ll share! Hehehe! Just proving a point! Hehehe

$uniQure NV (QURE.US)$ FDA Grants Breakthrough Therapy Designation To UniQure's AMT-130 For Treatment Of Huntington's Disease
Benzinga· 23 mins ago

1

2

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

$uniQure NV (QURE.US)$
Revolutionary Hemophilia B Treatment Eliminates Need for Regular Therapy in 94% of Patients

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Read more